Plain-English translation of NCT07475026 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether combined with —two medications that work in different ways to fight cancer—can help prevent liver cancer from returning after surgery. Normally, patients with early-stage, surgically removable liver cancer go straight to the operating room. This trial asks: what if we give the medication first, before surgery? The hope is that this approach will reduce the risk of cancer coming back and help patients live longer.
Even after successful surgery to remove a liver tumor, cancer often comes back in patients at high risk. Doctors need better ways to prevent this recurrence and improve long-term survival. Recent research suggests that this combination of medications may be effective and safe when given before surgery, so this trial is testing whether that promise holds true.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups: either surgery alone, or two rounds of medication given before your surgery. If you receive the medication, you will take it for several weeks before your operation, with regular clinic visits to check how you're tolerating the treatment and how your cancer is responding. After surgery, you will have follow-up visits to monitor your health and watch for any sign of cancer return. The study will track your progress for an extended period to see whether the medication approach reduces recurrence and improves long-term survival.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment target
~198 participants
Started
June 2026
Primary completion
January 2030
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in August 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Tianqiang Song
Tianjin Medical University Cancer Institute and Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.